|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C6orf226 |
Gene summary for C6ORF226 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C6orf226 | Gene ID | 441150 |
| Gene name | chromosome 6 open reading frame 226 | |
| Gene Alias | C6orf226 | |
| Cytomap | 6p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q5I0X4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 441150 | C6orf226 | LZE2D | Human | Esophagus | HGIN | 2.47e-05 | 1.08e+00 | 0.0642 |
| 441150 | C6orf226 | LZE2T | Human | Esophagus | ESCC | 2.97e-09 | 9.39e-01 | 0.082 |
| 441150 | C6orf226 | LZE4T | Human | Esophagus | ESCC | 1.20e-07 | 1.71e-01 | 0.0811 |
| 441150 | C6orf226 | LZE7T | Human | Esophagus | ESCC | 3.72e-07 | 3.39e-01 | 0.0667 |
| 441150 | C6orf226 | LZE8T | Human | Esophagus | ESCC | 8.60e-04 | 1.29e-01 | 0.067 |
| 441150 | C6orf226 | LZE20T | Human | Esophagus | ESCC | 1.99e-02 | 1.04e-01 | 0.0662 |
| 441150 | C6orf226 | LZE22D1 | Human | Esophagus | HGIN | 9.25e-04 | 1.40e-01 | 0.0595 |
| 441150 | C6orf226 | LZE22T | Human | Esophagus | ESCC | 9.47e-03 | 1.62e-01 | 0.068 |
| 441150 | C6orf226 | LZE24T | Human | Esophagus | ESCC | 6.18e-19 | 5.11e-01 | 0.0596 |
| 441150 | C6orf226 | LZE6T | Human | Esophagus | ESCC | 7.71e-05 | 3.36e-01 | 0.0845 |
| 441150 | C6orf226 | P1T-E | Human | Esophagus | ESCC | 2.55e-13 | 5.10e-01 | 0.0875 |
| 441150 | C6orf226 | P2T-E | Human | Esophagus | ESCC | 2.18e-13 | 1.65e-01 | 0.1177 |
| 441150 | C6orf226 | P4T-E | Human | Esophagus | ESCC | 8.31e-22 | 5.69e-01 | 0.1323 |
| 441150 | C6orf226 | P5T-E | Human | Esophagus | ESCC | 8.63e-22 | 1.02e-01 | 0.1327 |
| 441150 | C6orf226 | P8T-E | Human | Esophagus | ESCC | 7.33e-21 | 4.09e-01 | 0.0889 |
| 441150 | C6orf226 | P9T-E | Human | Esophagus | ESCC | 9.76e-17 | 3.69e-01 | 0.1131 |
| 441150 | C6orf226 | P10T-E | Human | Esophagus | ESCC | 2.00e-19 | 2.32e-01 | 0.116 |
| 441150 | C6orf226 | P11T-E | Human | Esophagus | ESCC | 3.96e-10 | 3.41e-01 | 0.1426 |
| 441150 | C6orf226 | P12T-E | Human | Esophagus | ESCC | 2.94e-39 | 7.37e-01 | 0.1122 |
| 441150 | C6orf226 | P15T-E | Human | Esophagus | ESCC | 2.00e-14 | 9.70e-02 | 0.1149 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C6orf226 | SNV | Missense_Mutation | novel | c.47N>T | p.Ser16Leu | p.S16L | Q5I0X4 | protein_coding | deleterious_low_confidence(0.04) | benign(0.022) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C6orf226 | SNV | Missense_Mutation | novel | c.104N>T | p.Pro35Leu | p.P35L | Q5I0X4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C6orf226 | SNV | Missense_Mutation | c.101N>C | p.Leu34Pro | p.L34P | Q5I0X4 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.873) | TCGA-MI-A75C-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| C6orf226 | SNV | Missense_Mutation | c.41C>G | p.Ser14Cys | p.S14C | Q5I0X4 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.505) | TCGA-91-6840-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C6orf226 | SNV | Missense_Mutation | novel | c.262N>A | p.Glu88Lys | p.E88K | Q5I0X4 | protein_coding | tolerated_low_confidence(0.16) | benign(0.003) | TCGA-96-A4JL-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | gemzar | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |